|Referral date||01 May 2011|
Scoped within Batch 17
|Closing date for invited submissions / evidence submission:||TBC|
|1st appraisal committee meeting:||TBC|
|Project manager:||Bijal Joshi|
|8 June 2012||
The Institute has now been informed by the manufacturer that it is not currently pursuing a licensing application for rivaroxaban in this indication, therefore, NICE has decided to suspend this appraisal on its current work programme for the time being.
As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.
|25 August 2011||
As you are aware, the Department of Health has asked us to carry out a single technology appraisal of rivaroxaban for the prevention of venous thromboembolism in people hospitalised for acute medical conditions.
Following on from advice received from the manufacturer, the dates for this appraisal will be confirmed once regulatory approval timelines are established.
The deadline for evidence submission, which was 3 October 2011, no longer applies in this instance.
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance